Fig. 1 · Structure
Documents & Downloads
LH1753
L-cystine Crystallization Inhibitor
LH1753 is an orally active L-cystine crystallization inhibitor that displays an EC50 of 29.5 nM. This compound is primarily utilized in research focused on cystinuria, where it aids in understanding the mechanisms and potential treatments related to cystine crystallization. Its potent inhibitory effect makes LH1753 a valuable tool for studies aimed at elucidating the pathways involved in cystine stone formation.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| Actions | Inhibitor |
| CAS Number | 2650492-10-5 |
| Applications | L-cystine Crystallization Inhibitor |
| Formula | C22H44Cl4N6O2S2 |
| Molecular Weight | 630.57 |
| SMILES | O=C([C@@H](N)CSSC[C@H](N)C(N1CCC2(NCCC2)CC1)=O)N3CCC4(NCCC4)CC3.Cl.Cl.Cl.Cl |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.